Recombinant Anti-CD55 x Anti-CA9 Bispecific Antibody (scIgG) (SCIGG-123)

Recombinant Anti-CD55 x Anti-CA9 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD55 and anti-CA9 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD55 & CA9

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Renal cell cancer (RCC); Solid tumors

Targets

Target 1

CD55

Gene ID

1604

UniProt ID

P08174

Alternative Names

CD55; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CR; TC; DAF; CROM; complement decay-accelerating factor; CD55 antigen

Target 2

CA9

Gene ID

768

UniProt ID

Q16790

Alternative Names

CA9; carbonic anhydrase 9; RCC-associated antigen G250; G250; CA-IX; carbonic anhydrase IX; MN; CAH9

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD55 x Anti-CA9 Bispecific Antibody (scIgG) (SCIGG-123). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD55 x Anti-CA9 Bispecific Antibody (scIgG) (CAT#: SCIGG-123)

Specifications

Targets

Customer Reviews and Q&As